Next Article in Journal
Analysis of Outcomes of the NRS 2002 in Patients Hospitalized in Nephrology Wards
Next Article in Special Issue
Effects of the Mediterranean Diet before and after Weight Loss on Eating Behavioral Traits in Men with Metabolic Syndrome
Previous Article in Journal
We Need Studies of the Mortality Effect of Vitamin A Supplementation, Not Surveys of Vitamin A Deficiency
Previous Article in Special Issue
Micronutrient Status in 153 Patients with Anorexia Nervosa
Article Menu
Issue 3 (March) cover image

Export Article

Nutrients 2017, 9(3), 281; doi:10.3390/nu9030281

Case Report
Sensory Neuronopathy Revealing Severe Vitamin B12 Deficiency in a Patient with Anorexia Nervosa: An Often-Forgotten Reversible Cause
1
Hôpital de La Casamance, 13400 Aubagne, France
2
Service de Médecine Interne, Hôpital Européen, 13003 Marseille, France
3
Service de Neurologie, CHU Bordeaux 33000 Bordeaux, France
*
Author to whom correspondence should be addressed.
Received: 17 February 2017 / Accepted: 13 March 2017 / Published: 15 March 2017

Abstract

:
Vitamin B12 (B12) deficiency is known to be associated with various neurological manifestations. Although central manifestations such as dementia or subacute combined degeneration are the most classic, neurological manifestations also include sensory neuropathies. However, B12 deficiency is still rarely integrated as a potential cause of sensory neuronopathy. Moreover, as many medical conditions can falsely normalize serum B12 levels even in the context of a real B12 deficiency, some cases may easily remain underdiagnosed. We report the illustrating case of an anorexic patient with sensory neuronopathy and consistently normal serum B12 levels. After all classical causes of sensory neuronopathy were ruled out, her clinical and electrophysiological conditions first worsened after folate administration, but finally improved dramatically after B12 administration. B12 deficiency should be systematically part of the etiologic workup of sensory neuronopathy, especially in a high risk context such as anorexia nervosa.
Keywords:
sensory neuropathy; cobalamin deficiency; vitamin B12; anorexia nervosa

1. Introduction

Vitamin B12 (B12) or cobalamin deficiency is a real public health issue, since it has been reported to occur in up to 20% of the elderly and up to 30% in specific subgroups of patients above 70 years [1,2]. The most characteristic manifestations of severe deficiency are haematological (i.e., macrocytic anemia) and central neurological manifestations such as reversible dementia or subacute combined degeneration [3]. However, peripheral neuropathies account for 30% to 50% of the neurological symptoms associated with B12 deficiency [4]. They are mostly symmetrical, length-dependent axonal sensory and sometimes sensorimotor neuropathies [5]. To date, B12 deficiency has not been included among the classical causes of sensory neuronopathies, which usually have an acute onset, are sometimes asymmetrical, or have a non-length-dependent distribution [6]. Importantly, the fact that B12 serum levels assessment can be falsely normalized by various medical conditions (including acute and chronic liver diseases, often of alcoholic origin, various neoplasias, malignant hemopathies such as myeloproliferative diseases, and renal insufficiency), a situation often termed as “functional B12 deficiency”, may have participated to the underdiagnosis of this association [7,8]. Indeed, in the cases where the serum levels are in the normal range but the index of suspicion for a B12 deficiency remains strong, the diagnosis should rely on either surrogate biomarkers for B12 deficiency (high homocysteine or methylmalonic acid (MMA) levels, medullary aspiration findings) and/or on the improvement under B12 supplementation. However, in practice, these additional investigations are rarely performed [8].
We report here an illustrating case of sensory neuronopathy in the context of chronic anorexia with dramatic improvement after vitamin B12 treatment.

2. Case Presentation

A 30 year-old female patient, with no past medical history, presented with painful paresthesia in the feet, which extended within two weeks to the hands and lips. She had lost 10 kg during the last four months in a context of anorexia nervosa. Clinical examination revealed only skin hyperpigmentation. The neurological examination showed the existence of diffuse areflexia and hypoesthesia in all four limbs. No proprioceptive ataxia or weakness was detected. The biological tests showed low plasma folate level (vitamin B9) (4.5 nmol/L for normal value > 7 nmol/L) with normal serum B12 or vitamin E levels. The electrophysiological study was in favor of a severe non-symmetrical, non-length-dependent sensory neuropathy involving all four limbs, with an electro-clinical pattern of sensory neuronopathy (Table 1). The motor nerve conduction study was normal, without slowing of nerve conduction velocities or any conduction block, and the evoked motor potentials (studied in all four limbs using transcranial magnetic stimulation) were also normal.
The cerebrospinal fluid analysis (cytology, protein and glucose levels, immunoelectrophoresis) and brain/spinal cord MRI findings were normal. The whole-body CT-scan was normal. The immunological tests including anti-neuronal, anti-ganglioside, anti-SSA/SSB were negative. The salivary gland biopsy was normal. No monoclonal gammopathy or immunoglobulin light chain was found. The HIV blood test was negative, as other usual serologies (EBV, CMV, hepatitis, Lyme disease); Treponema pallidum particle agglutination assay (TP-PA) and venereal disease research laboratory test (VDRL) turned out to be negative.
The patient was given vitamins B1, B6, and B9 at usual doses. Cutaneous symptoms responded well to this treatment, but she was admitted to hospital three months later because of a subacute proprioceptive ataxia causing frequent falls. Owing to her persistent state of anorexia, she had then lost 10 more kg. She was still suffering from painful paresthesia in wrists and ankles despite continuous treatment with vitamins B1, B6, and B9. She was only able to walk a few meters unaided. At physical examination, no pallesthesia was observed at levels of the knees. No motor symptoms or pyramidal sign were detected. She presented no orthostatic hypotension nor other signs of dysautonomia. The folate serum level was then normalized (34 nmol/L) and B12 level still in the normal range (314 pmol/L, normal value > 220 pmol/L), but hyperhomocysteinemia (25 µmol/L; normal value < 15 µmol/L) was observed (without renal insufficiency), as well as macrocytosis (mean corpuscular volume (MCV): 102 fl, normal value < 100 fl) without anemia (complete blood count was strictly normal), suggestive of B12 deficiency. Anti-transglutaminase, anti-endomysium, and intrinsic factor/gastric parietal cell antibodies were negative and oesogastroduodenal fibroscopy was normal.
The patient was therefore given daily 1000 µg intramuscular injections of B12 for two months. Although anorexia persisted, this treatment significantly decreased painful paresthesia within three months in parallel of a normalization of homocysteinemia and MCV. Five months later, her ability to walk was no longer restricted. At last examination, nine months after B12 administration, there was no more symptom in the upper limbs, and pallesthesia was quite normal in the feet with normal walking. Electrophysiological tests confirmed a progressive increase of the amplitude of sensory nerve action potential (SNAP) with time (Table 1).

3. Discussion and Conclusions

Vitamin B12 deficiency is usually associated with various hematological, gastrointestinal and neurological/neuropsychiatric disorders [3]. Hematological manifestations may include anemia with a macrocytic blood picture and megaloblastic bone marrow, as well as isolated macrocytosis, as in our patient, and even in the complete absence of hematological manifestations in some patients with clear neurological manifestations [5,9]. Indeed, neurological manifestations may be the earliest and often the only manifestation of B12 deficiency [9].
While the main neurological complication is peripheral neuropathy, subacute combined degeneration, and optic nerve neuropathy can occur. Other rare manifestations include dementia, cerebellar ataxia, leukoencephalopathy, orthostatic tremor, myoclonus, ophthalmoplegia, catatonia, vocal cord paralysis, syringomyelia-like distribution of motor and sensory deficits, and autonomic dysfunction. Clinical and pathological involvement of the peripheral nervous system has been well described with B12 deficiency, usually with electrophysiological abnormalities suggestive of a length-dependent sensorimotor axonopathy [5].
We describe here a severe case of ataxia due to a sensory neuronopathy that was dramatically improved after B12 administration in a patient suffering severe anorexia nervosa. Because of the known poor sensitivity of the radio-immunological methods to detect it, a functional B12 deficiency was suspected because of the clinical context and in spite of repeated normal blood serum B12 levels [7]. Indeed, from measured total serum B12, only a small and variable proportion of B12 is active, so that metabolic B12 deficiency is common in patients with a serum B12 in the reference range [10]. To be reasonably sure that total serum B12 is adequate, some have proposed to consider as correct only levels above ~400 pmol/L [11,12]. Especially below that cut-off, as in our case, confirmatory tests are needed to assess adequacy of functional B12: measurement of methylmalonic acid, or in folate-replete patients, total homocysteine [8]. The worsening under folate therapy was also evocative of the process termed the ‘folate trap’ [13]. Indeed, folates and B12 both act as cofactors in the process of DNA synthesis. Giving folates to patients with B12 deficiency may mobilize the remaining stocks of B12 required to synthesize the nucleic acids on which fast cell replacement processes depend. This mobilization of the last remaining B12 supplies may occur to the detriment of other biochemical reactions involving B12, such as those resulting in the formation of methionine and hence that of myelin. Ultimately, a therapeutic test with B12 supplementation may be mandatory to confirm that B12 deficiency is the cause of the observed neurological manifestations. Importantly, this test may be worthwhile even in patients with an alternative cause of peripheral neuropathies. In a recent study, Solomon observed that 83% of 78 patients with neuropathy (including 35 patients with other known causes of neuropathy) improved after having been treated with oral or parenteral B12 [14]. Although patients with severe B12 deficiency with severe clinical complications first need parenteral B12, oral B12 is usually adequate to achieve target levels [15], so that as long as anorexia persists, patients should be given oral B12 supplements in the long term.
Sensory neuronopathies are characterized by the primary involvement of sensory neurons in the dorsal root ganglia [16]. New diagnostic criteria for sensory neuronopathies have been published [5,17]. Using these criteria, our patient was classified in the ‘possible sensory neuronopathy’ group. Indeed, the electrophysiological study including 14 sensory nerves showed an asymmetrical and a more pronounced involvement of the proximal sensory nerves (cutaneous median and lateral forearm from both upper limb) compared to distal nerves (medial, radial and ulnar nerves) in favor of a non-length-dependent neuropathy. Finally, paresthesia in the lips is not a classical sensory localisation of length-dependent axonopathy. The known etiological causes of sensory neuronopathies are paraneoplastic, toxic, dysimmune, nutritional (lack of vitamin E, nicotinic acid, and riboflavin), infectious, and genetic causes. Approximately 50% of the cases of sensory neuronopathy are said to be ‘idiopathic’ [16], but B12 deficiency has not been included so far among the definite causes. Pathological findings on totally gastrectomized rats (a murine model for B12 deficiency) also support this causality. Indeed, it was reported that non-vasogenic edema present in endoneurium of the dorsal root ganglia disappeared in response to B12 administration [18].
In the case of our patient, there seems to have been a link between B12 deficiency and sensory neuronopathy: (a) the classical etiological patterns were ruled out; (b) the neurological symptoms worsened after folate administration (‘folate trap’); and (c) the clinical and electrophysiological findings improved dramatically in response to B12 treatment concomitantly with the normalisation of homocysteinemia and MCV.
Vitamin B12 deficiency has not yet been recognized as one of the causes of sensory neuronopathy, mainly because of the poor sensitivity of radio-immunological methods of determination and/or by the absence of systematic screening in the presence of alternative concomitant causes. In patients at high risk such as those with anorexia nervosa, it is therefore essential to identify as quickly as possible this deficiency, even if B12 serum levels are normal or paradoxically high [19], since a specific treatment is available, the time elapsing before its introduction being the main prognostic factor.

Author Contributions

J.F., L.C. and S.M. analyzed and interpreted the patient data and contributed in writing the manuscript. All authors read and approved the final manuscript.

Conflicts of Interest

The authors declare no conflict of interest.

Abbreviations

B12vitamin B12
CMVcytomegalovirus
CT-scancomputerized tomography scanner
DNAdeoxyribonucleic acid
EBVEpstein-Barr virus
HIVhuman immunodeficiency virus
MRImagnetic resonance imaging
SNAPsensory nerve action potential
TP-PATreponema pallidum particle agglutination assay
VDRLvenereal disease research laboratory test

References

  1. Andrès, E.; Loukili, N.H.; Noel, E.; Kaltenbach, G.; Abdelgheni, M.B.; Perrin, A.E.; Noblet-Dick, M.; Maloisel, F.; Schlienger, J.L.; Blicklé, J.F. Vitamin B12 (cobalamin) deficiency in elderly patients. CMAJ 2004, 171, 251–259. [Google Scholar] [CrossRef] [PubMed]
  2. Spence, J.D. Nutrition and stroke prevention. Stroke 2006, 37, 2430–2435. [Google Scholar] [CrossRef] [PubMed]
  3. Kumar, N. Neurologic aspects of cobalamin (B12) deficiency. Handb. Clin. Neurol. 2014, 120, 915–926. [Google Scholar] [PubMed]
  4. Franques, J.; Gazzola, S. Neuropathies métaboliques et carentielles: Mise au point sur le diabète, les carences en vitamine B12 et les carences en cuivre. Rev. Neurol. (Paris) 2013, 169, 991–996. [Google Scholar] [CrossRef] [PubMed]
  5. Saperstein, D.S.; Wolfe, G.I.; Gronseth, G.S.; Nations, S.P.; Herbelin, L.L.; Bryan, W.W.; Barohn, R.J. Challenges in the identification of cobalamin-deficiency polyneuropathy. Arch. Neurol. 2003, 60, 1296–1301. [Google Scholar] [CrossRef] [PubMed]
  6. Camdessanché, J.P.; Jousserand, G.; Ferraud, K.; Vial, C.; Petiot, P.; Honnorat, J.; Antoine, J.C. The pattern and diagnostic criteria of sensory neuronopathy: A case-control study. Brain 2009, 132, 1723–1733. [Google Scholar] [CrossRef] [PubMed]
  7. Solomon, L.R. Cobalamin-responsive disorders in the ambulatory care setting: Unreliability of cobalamin, methylmalonic acid, and homocysteine testing. Blood 2005, 105, 978–985. [Google Scholar] [CrossRef] [PubMed]
  8. Chiche, L.; Mancini, J.; Arlet, J.B. BDOSE Study Investigators. Indications for cobalamin level assessment in departments of internal medicine: A prospective practice survey. Postgrad. Med. J. 2013, 89, 560–565. [Google Scholar] [CrossRef] [PubMed]
  9. Ralapanawa, D.M.; Jayawickreme, K.P.; Ekanayake, E.M.; Jayalath, W.A. B12 deficiency with neurological manifestations in the absence of anaemia. BMC Res. Notes 2015, 8, 458. [Google Scholar] [CrossRef] [PubMed]
  10. Spence, J.D. Metabolic vitamin B12 deficiency: A missed opportunity to prevent dementia and stroke. Nutr. Res. 2016, 36, 109–116. [Google Scholar] [CrossRef] [PubMed]
  11. Vogiatzoglou, A.; Oulhaj, A.; Smith, A.D.; Nurk, E.; Drevon, C.A.; Ueland, P.M.; Vollset, S.E.; Tell, G.S.; Refsum, H. Determinants of plasma methylmalonic acid in a large population: Implications for assessment of vitamin B12 status. Clin. Chem. 2009, 55, 2198–2206. [Google Scholar] [CrossRef] [PubMed]
  12. Bang, H.; Mazumdar, M.; Spence, J.D. Tutorial in biostatistics: Analyzing associations between total plasma homocysteine and B vitamins using optimal categorization and segmented regression. Neuroepidemiology 2006, 27, 188–200. [Google Scholar] [CrossRef] [PubMed]
  13. Gutierrez, M.; Franques, J.; Faivre, A.; Koric, L.; Chiche, L.; Attarian, S.; Pouget, J. Diagnostic d’une carence en vitamine B12 ou le signe de l’ordonnance. Rev. Neurol. (Paris) 2010, 166, 242–247. [Google Scholar] [CrossRef] [PubMed]
  14. Solomon, L.R. Vitamin B12-responsive neuropathies: A case series. Nutr. Neurosci. 2016, 19, 162–168. [Google Scholar] [CrossRef] [PubMed]
  15. Van Walraven, C.G.; Austin, P.; Naylor, C.D. Use of vitamin B12 injections among elderly patients by primary care. CMAJ 1999, 161, 146–149. [Google Scholar] [PubMed]
  16. Sghirlanzoni, A.; Pareyson, D.; Lauria, G. Sensory neuron diseases. Lancet Neurol. 2005, 4, 349–361. [Google Scholar] [CrossRef]
  17. Antoine, J.C.; Robert-Varvat, F.; Maisonobe, T.; Créange, A.; Franques, J.; Mathis, S.; Delmont, E.; Kuntzer, T.; Lefaucheur, J.P.; Pouget, J.; et al. Testing the validity of a set of diagnostic criteria for sensory neuronopathies: A francophone collaborative study. J. Neurol. 2014, 261, 2093–2100. [Google Scholar] [CrossRef] [PubMed]
  18. Tredici, G.; Buccellato, F.R.; Cavaletti, G.; Scalabrino, G. Subacute combined degeneration in totally gastrectomized rats: An ultrastructural study. J. Submicrosc. Cytol. Pathol. 1998, 30, 165–173. [Google Scholar] [PubMed]
  19. Corbetta, F.; Tremolizzo, L.; Conti, E.; Ferrarese, C.; Neri, F.; Bomba, M.; Nacinovich, R. Paradoxical increase of plasma vitamin B12 and folates with disease severity in anorexia nervosa. Int. J. Eat. Disord. 2015, 48, 317–322. [Google Scholar] [CrossRef] [PubMed]
Table 1. Evolution of amplitude of sensory nerve action potential (SNAP) on three successive electrophysiological studies of sensory nerves: initial study (M0) before treatment, second study five months after (M5), then third study nine months after the vitamin B12 treatment initiation (M9).
Table 1. Evolution of amplitude of sensory nerve action potential (SNAP) on three successive electrophysiological studies of sensory nerves: initial study (M0) before treatment, second study five months after (M5), then third study nine months after the vitamin B12 treatment initiation (M9).
M0M5M9
right sidemedian nerve4.4 µV8.6 µV11 µV
ulnar nerve6 µV9.3 µV10 µV
radial nerve5 µV10 µV11 µV
cutaneous median forearm nerve0 µV7.5 µV8 µV
cutaneous lateral forearm nerve0 µV0 µV4.3 µV
sural nerve0 µV0 µV3 µV
fibular nerve0 µV0 µV0 µV
left sidemedian nerve4.6 µV5.6 µV9 µV
ulnar nerveNO2.5 µV6 µV
radial nerve5.3 µV5.9 µV11.4 µV
cutaneous median forearm nerve0 µV0 µV8 µV
cutaneous lateral forearm nerve0 µV0 µV1.4 µV
sural nerve0 µV1.2 µV6.4 µV
fibular nerve0 µV0 µV0 µV
Nutrients EISSN 2072-6643 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top